- Home
- RVPH vs BOLD Comparison
RVPH vs BOLD Comparison
Compare RVPH & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- BOLD
- Stock Information
- Founded
- RVPH 2006
- BOLD 2018
- Country
- RVPH United States
- BOLD United States
- Employees
- RVPH N/A
- BOLD N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- RVPH Health Care
- BOLD
- Exchange
- RVPH Nasdaq
- BOLD Nasdaq
- Market Cap
- RVPH 26.6M
- BOLD 24.4M
- IPO Year
- RVPH N/A
- BOLD 2024
- Fundamental
- Price
- RVPH $0.47
- BOLD $1.27
- Analyst Decision
- RVPH Strong Buy
- BOLD Buy
- Analyst Count
- RVPH 5
- BOLD 3
- Target Price
- RVPH $9.00
- BOLD $4.00
- AVG Volume (30 Days)
- RVPH 3.4M
- BOLD 200.8K
- Earning Date
- RVPH 08-13-2025
- BOLD 08-11-2025
- Dividend Yield
- RVPH N/A
- BOLD N/A
- EPS Growth
- RVPH N/A
- BOLD N/A
- EPS
- RVPH N/A
- BOLD N/A
- Revenue
- RVPH N/A
- BOLD N/A
- Revenue This Year
- RVPH N/A
- BOLD N/A
- Revenue Next Year
- RVPH N/A
- BOLD N/A
- P/E Ratio
- RVPH N/A
- BOLD N/A
- Revenue Growth
- RVPH N/A
- BOLD N/A
- 52 Week Low
- RVPH $0.30
- BOLD $1.00
- 52 Week High
- RVPH $4.28
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- RVPH 47.70
- BOLD N/A
- Support Level
- RVPH $0.38
- BOLD N/A
- Resistance Level
- RVPH $0.45
- BOLD N/A
- Average True Range (ATR)
- RVPH 0.03
- BOLD 0.00
- MACD
- RVPH 0.02
- BOLD 0.00
- Stochastic Oscillator
- RVPH 93.07
- BOLD 0.00
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.